Christopher K. Mirabelli's most recent trade in Cypherpunk Technologies Inc. was a trade of 94,050 Restricted Stock Units done . Disclosure was reported to the exchange on Dec. 23, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Dec 2025 | 94,050 | 94,050 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Other type of transaction at price $ 0.00 per share. | 23 Dec 2025 | 2,136 | 0 (0%) | 0% | 0 | Common Stock | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Other type of transaction at price $ 0.00 per share. | 23 Dec 2025 | 712 | 21,626 (0%) | 0% | 0 | Common Stock | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Sale of securities on an exchange or to another person at price $ 3.14 per share. | 17 Nov 2025 | 414,479 | 2,136 (0%) | 1% | 3.1 | 1,301,464 | Common Stock |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Sale of securities on an exchange or to another person at price $ 3.14 per share. | 17 Nov 2025 | 261,840 | 416,616 (1%) | 1% | 3.1 | 822,178 | Common Stock |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Nov 2025 | 74,700 | 74,700 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 22,500 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 22,500 | 27,586 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Chairman of the Board | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.32 per share. | 28 Mar 2025 | 6,672 | 20,914 (0%) | 0% | 0.3 | 2,112 | Common Stock |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Chairman of the Board | 13 Nov 2024 | 2,136 | 0 | - | - | Warrant (Right to Buy) | ||
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Chairman of the Board | 13 Nov 2024 | 2,136 | 678,456 (2%) | 0% | 2.8 | 6,024 | Common Stock | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Oct 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Mirabelli Christopher K. | Director, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2024 | 85,000 | 85,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Mirabelli Christopher K. | Director, Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 5,000 | 5,086 (0%) | 0% | - | Common Stock | |
| Leap Therapeutics Inc | K. Mirabelli Christopher | Director, Chairman of the Board | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Jan 2024 | 5,000 | 0 | - | - | Restricted Stock Units | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Aug 2023 | 70,000 | 70,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Mar 2023 | 500,000 | 500,000 | - | - | Stock Option (Right to Buy) | |
| Leap Therapeutics Inc | Christopher K. Mirabelli | Director, Ten Percent Owner, Chairman of the Board | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 225,000 | 225,000 | - | - | Restricted Stock Units |